ES2870596T3 - Inmunoterapia basada en indolamina 2,3-dioxigenasa - Google Patents

Inmunoterapia basada en indolamina 2,3-dioxigenasa Download PDF

Info

Publication number
ES2870596T3
ES2870596T3 ES17194619T ES17194619T ES2870596T3 ES 2870596 T3 ES2870596 T3 ES 2870596T3 ES 17194619 T ES17194619 T ES 17194619T ES 17194619 T ES17194619 T ES 17194619T ES 2870596 T3 ES2870596 T3 ES 2870596T3
Authority
ES
Spain
Prior art keywords
ido
hla
cells
peptide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17194619T
Other languages
English (en)
Spanish (es)
Inventor
Mads Hald Andersen
Per Thor Straten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Application granted granted Critical
Publication of ES2870596T3 publication Critical patent/ES2870596T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES17194619T 2008-04-17 2009-04-17 Inmunoterapia basada en indolamina 2,3-dioxigenasa Active ES2870596T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200800565 2008-04-17

Publications (1)

Publication Number Publication Date
ES2870596T3 true ES2870596T3 (es) 2021-10-27

Family

ID=40873320

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17194619T Active ES2870596T3 (es) 2008-04-17 2009-04-17 Inmunoterapia basada en indolamina 2,3-dioxigenasa
ES09753556.1T Active ES2657963T3 (es) 2008-04-17 2009-04-17 Inmunoterapia basada en indolamina 2,3-dioxigenasa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09753556.1T Active ES2657963T3 (es) 2008-04-17 2009-04-17 Inmunoterapia basada en indolamina 2,3-dioxigenasa

Country Status (20)

Country Link
US (7) US9433666B2 (enExample)
EP (3) EP2280721B1 (enExample)
JP (2) JP2011520783A (enExample)
CN (2) CN104056261B (enExample)
AU (1) AU2009253539B2 (enExample)
CA (1) CA2721150C (enExample)
CY (2) CY1120352T1 (enExample)
DK (2) DK2280721T3 (enExample)
ES (2) ES2870596T3 (enExample)
HR (2) HRP20180282T1 (enExample)
HU (2) HUE037973T2 (enExample)
IL (1) IL208781A (enExample)
LT (2) LT2280721T (enExample)
NO (1) NO2280721T3 (enExample)
NZ (1) NZ588757A (enExample)
PL (2) PL3320912T3 (enExample)
PT (2) PT2280721T (enExample)
SI (2) SI2280721T1 (enExample)
WO (1) WO2009143843A1 (enExample)
ZA (1) ZA201008056B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2280721T3 (da) 2008-04-17 2018-01-29 Io Biotech Aps Indoleamin-2, 3-dioxygenasebaseret immunterapi
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
CA2947650C (en) 2014-05-29 2021-04-27 Spring Bioscience Corporation Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
PL3193917T3 (pl) 2014-09-17 2022-01-17 Io Biotech Aps Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty
CN106148276A (zh) * 2015-04-16 2016-11-23 中国科学院上海生命科学研究院 间充质干细胞在制备治疗神经退行性疾病的药物中的应用
EA201890148A1 (ru) 2015-06-29 2018-05-31 Озе Иммьюнотерапьютикс Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидов
IL257940B (en) 2015-09-16 2022-08-01 Herlev Hospital Vaccines that include the CC motif. Chemokine 22 or fragments thereof
HUE064857T2 (hu) * 2016-03-04 2024-04-28 Io Biotech Aps Kombinációs terápia a rák ellen
CN109803674A (zh) 2016-06-10 2019-05-24 Io生物技术公司 Calr和jak2疫苗组合物
AU2017340387A1 (en) * 2016-10-04 2019-05-02 University Of Florida Research Foundation, Inc. Targeted effector proteins and uses thereof
CN110249056A (zh) * 2016-10-14 2019-09-17 苏黎世大学 用于前列腺癌诊断及预后的吲哚胺-2,3-双加氧酶检测
CA3050299A1 (en) * 2017-01-20 2018-07-26 Atara Biotherapeutics, Inc. Methods of treating multiple sclerosis using autologous t cells
EA201991444A1 (ru) 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
WO2018138257A1 (en) * 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
AU2018212584B2 (en) * 2017-01-27 2020-12-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2019075062A1 (en) 2017-10-11 2019-04-18 University Of Florida Research Foundation MODIFIED GAL-1 PROTEINS AND USES THEREOF
MX2020005454A (es) 2017-11-27 2020-08-27 Ose Immunotherapeutics Tratamiento de cancer mejorado.
WO2020087051A1 (en) 2018-10-26 2020-04-30 University Of Florida Research Foundation, Incorporated Targeted chondroitinase abc fusion proteins and complexes thereof
US12577282B2 (en) 2019-02-28 2026-03-17 University Of Florida Research Foundation, Incorporated Galectin-1/ galectin-3 chimeras and multivalent proteins
CN109758467B (zh) * 2019-03-08 2020-12-25 中国农业科学院兰州兽医研究所 一种吉西他滨在制备预防口蹄疫病毒感染的药物中的应用
JP2022554217A (ja) * 2019-10-23 2022-12-28 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 養子免疫療法
US12582709B2 (en) 2020-07-02 2026-03-24 The Regents Of The University Of California Persistent memory T-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways
CN112881269A (zh) * 2021-02-23 2021-06-01 浙江正熙生物技术股份有限公司 一种流式荧光检测试剂的质量检测方法
GB202103673D0 (en) 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
CN114657158B (zh) * 2022-05-25 2022-10-21 深圳吉诺因生物科技有限公司 Ido1相关疫苗及其应用
WO2024155564A1 (en) * 2023-01-17 2024-07-25 Regeneron Pharmaceuticals, Inc. Inositol polyphosphate multikinase (ipmk) therapeutic agents or indoleamine 2,3-dioxygenase 2 (ido2) agonists for use in treating b27-negative uveitis
JP2026507007A (ja) * 2023-02-21 2026-02-27 サルバイタス、インコーポレイテッド 組換えファージ、プロバイオティクスワクチンおよび治療薬、関連組成物および使用方法
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine
WO2025189043A2 (en) * 2024-03-07 2025-09-12 Salvitus, Inc. Oral vaccine compositions and related methods
WO2025242193A1 (zh) * 2024-05-24 2025-11-27 重庆医科大学 博来霉素作为免疫增强剂的用途
WO2026008025A1 (en) * 2024-07-03 2026-01-08 Everest Medicines (China) Co., Ltd. Ido1 cancer vaccines and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
WO1997000966A1 (en) * 1995-06-20 1997-01-09 Merck & Co., Inc. Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
CN1221349A (zh) 1996-06-12 1999-06-30 郭亚军 细胞疫苗、免疫治疗以及它们的制备方法
CN1223688A (zh) * 1996-06-27 1999-07-21 纳幕尔杜邦公司 对羟基苯丙酮酸双加氧酶的植物基因
DE19730066A1 (de) * 1997-07-14 1999-01-21 Basf Ag DNA-Sequenz codierend für eine Hydroxyphenylpyruvatdioxygenase und deren Überproduktion in Pflanzen
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
WO2000066764A1 (en) 1999-05-03 2000-11-09 Ludwig Institute For Cancer Research Methods for increasing t cell proliferation
EP1425302A2 (en) 2001-01-24 2004-06-09 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002071928A2 (en) 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US20060292618A1 (en) 2002-04-12 2006-12-28 Mellor Andrew L Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
EP1501918A4 (en) 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
DE10229872A1 (de) * 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004053075A2 (en) 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
CA2509103A1 (en) 2002-12-13 2004-07-01 Mitra Medical Technology Ab Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
DE10261223A1 (de) 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
WO2004094409A1 (en) 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20050186289A1 (en) * 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
WO2005036127A2 (en) 2003-10-02 2005-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying target cell cytolytic lymphocytes in a sample
EP1773846A4 (en) * 2004-07-13 2008-10-08 Univ British Columbia INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE (IDO)
WO2006056304A2 (en) 2004-11-23 2006-06-01 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
DK1853305T3 (en) 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
SG10202001007TA (en) * 2005-09-23 2020-03-30 Tigenix Sau Cell populations having immunoregulatory activity, method for isolation and uses
US20070203140A1 (en) 2006-02-09 2007-08-30 Combs Andrew P N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
WO2007115068A2 (en) 2006-03-30 2007-10-11 Indiana University Research And Technology Corporation Genetic variants in the indoleamine 2,3-dioxygenase gene
WO2008143668A2 (en) * 2006-05-18 2008-11-27 Lankenau Institute For Medical Research Indoleamine-2, 3-dioxygenase-2
WO2008085828A2 (en) * 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
DK2280721T3 (da) 2008-04-17 2018-01-29 Io Biotech Aps Indoleamin-2, 3-dioxygenasebaseret immunterapi

Also Published As

Publication number Publication date
CA2721150A1 (en) 2009-12-03
DK3320912T3 (da) 2021-05-31
JP6016966B2 (ja) 2016-10-26
DK2280721T3 (da) 2018-01-29
CY1120352T1 (el) 2019-07-10
CY1124279T1 (el) 2022-07-22
PL3320912T3 (pl) 2021-10-25
NZ588757A (en) 2012-05-25
ZA201008056B (en) 2011-07-27
EP2280721A1 (en) 2011-02-09
AU2009253539A1 (en) 2009-12-03
PL2280721T3 (pl) 2018-04-30
PT2280721T (pt) 2018-02-16
CN102088994B (zh) 2014-06-25
CN104056261B (zh) 2017-01-11
CN102088994A (zh) 2011-06-08
US11324813B2 (en) 2022-05-10
US20250319159A1 (en) 2025-10-16
LT3320912T (lt) 2021-07-12
US12233103B2 (en) 2025-02-25
US20230233657A1 (en) 2023-07-27
JP2015129182A (ja) 2015-07-16
US20220202922A1 (en) 2022-06-30
LT2280721T (lt) 2018-02-12
EP3320912B1 (en) 2021-03-31
EP3320912A1 (en) 2018-05-16
US20110318372A1 (en) 2011-12-29
HRP20210766T1 (hr) 2021-07-23
PT3320912T (pt) 2021-05-24
US20220249641A1 (en) 2022-08-11
NO2280721T3 (enExample) 2018-04-14
US20170049868A1 (en) 2017-02-23
US11648302B2 (en) 2023-05-16
SI3320912T1 (sl) 2021-08-31
US9433666B2 (en) 2016-09-06
HRP20180282T1 (hr) 2018-03-23
HUE055338T2 (hu) 2021-11-29
US10258678B2 (en) 2019-04-16
IL208781A0 (en) 2010-12-30
ES2657963T3 (es) 2018-03-07
SI2280721T1 (en) 2018-02-28
AU2009253539B2 (en) 2014-03-20
HUE037973T2 (hu) 2018-09-28
CN104056261A (zh) 2014-09-24
JP2011520783A (ja) 2011-07-21
US20190201512A1 (en) 2019-07-04
EP3915570A1 (en) 2021-12-01
CA2721150C (en) 2017-09-26
EP2280721B1 (en) 2017-11-15
IL208781A (en) 2017-09-28
WO2009143843A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
ES2657963T3 (es) Inmunoterapia basada en indolamina 2,3-dioxigenasa
JP7491965B2 (ja) ネオ抗原およびその使用方法
CN112584852A (zh) 新抗原及其用途
CN112638404A (zh) 新抗原及其用途
JP2022551918A (ja) マルチドメインタンパク質ワクチン
CN106999557A (zh) 包含色氨酸2,3‑双加氧酶或其片段的疫苗组合物
HK1247114B (en) Indoleamine 2, 3-dioxygenase based immunotherapy
RU2773273C2 (ru) Неоантигены и способы их использования
HK40050845A (en) Neoantigens and uses thereof
HK40050847A (en) Neoantigens and uses thereof